{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:29Z","timestamp":1790806829482,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","aaojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ophtha.2017.03.018","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T00:46:47Z","timestamp":1492044407000},"page":"1156-1164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity"],"prefix":"10.1016","volume":"124","author":[{"given":"Qiujing","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-1460","authenticated-orcid":false,"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunda","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3245-5520","authenticated-orcid":false,"given":"Yi-an","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiquan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.ophtha.2017.03.018_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"key":"10.1016\/j.ophtha.2017.03.018_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF02482615","article-title":"Results of U.S. randomized clinical trial of cryotherapy for ROP (CRYO-ROP)","volume":"74","author":"Palmer","year":"1990","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.03.018_bib3","first-page":"233","article-title":"Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.ophtha.2017.03.018_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2017.03.018_bib5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":"Effects and complications of\u00a0bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan","volume":"118","author":"Wu","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.03.018_bib6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan","volume":"155","author":"Wu","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.03.018_bib7","first-page":"102582","article-title":"Outcomes and prognostic factors of intravitreal bevacizumab monotherapy in zone I stage 3+ and aggressive posterior retinopathy of prematurity","volume":"2015","author":"Nicoar\u0103","year":"2015","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.03.018_bib8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajo.2009.06.014","article-title":"Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies","volume":"148","author":"Csaky","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.03.018_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2147\/DDDT.S40215","article-title":"Aflibercept in wet AMD: specific role and optimal use","volume":"7","author":"Semeraro","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ophtha.2017.03.018_bib10","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","article-title":"Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity","volume":"91","author":"Hoerster","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.03.018_bib11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of\u00a0ranibizumab, an anti-vascular endothelial growth factor\u00a0antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.03.018_bib12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.03.018_bib13","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.03.018_bib14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.03.018_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ophtha.2016.06.055","article-title":"Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity","volume":"123","author":"Toy","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.03.018_bib16","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.03.018_bib17","first-page":"6","article-title":"Effects of ranibizumab in zone I and zone II retinopathy of prematurity patients","volume":"31","author":"Chen","year":"2015","journal-title":"Chinese J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.03.018_bib18","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.03.018_bib19","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.03.018_bib20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"Tahija","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.03.018_bib21","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.03.018_bib22","first-page":"2","article-title":"Avastin as monotherapy for retinopathy of prematurity","volume":"14","author":"Mintz-Hittner","year":"2010","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2017.03.018_bib23","first-page":"457","article-title":"Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity","volume":"14","author":"Jang","year":"2010","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2017.03.018_bib24","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/eye.2012.111","article-title":"Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity","volume":"26","author":"Lee","year":"2012","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2017.03.018_bib25","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/eye.2009.156","article-title":"Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity","volume":"24","author":"Zepeda-Romero","year":"2010","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2017.03.018_bib26","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.03.018_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","article-title":"Retinopathy of prematurity","volume":"10","author":"Chen","year":"2007","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ophtha.2017.03.018_bib28","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of\u00a0retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2017.03.018_bib29","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ajo.2009.05.031","article-title":"A\u00a0systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity","volume":"148","author":"Micieli","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.03.018_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.exer.2014.10.016","article-title":"The role of CTGF in diabetic retinopathy","volume":"133","author":"Klaassen","year":"2015","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2017.03.018_bib31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.clp.2014.08.011","article-title":"Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity","volume":"41","author":"Hartnett","year":"2014","journal-title":"Clin Perinatol"},{"key":"10.1016\/j.ophtha.2017.03.018_bib32","doi-asserted-by":"crossref","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","article-title":"Are we there yet? Bevacizumab therapy for retinopathy of prematurity","volume":"98","author":"Darlow","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.ophtha.2017.03.018_bib33","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.03.018_bib34","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/IAE.0000000000000535","article-title":"Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection","volume":"35","author":"Hong","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.03.018_bib35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.03.018_bib36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/aos.12266","article-title":"Intravitreal low-dosage bevacizumab for retinopathy of prematurity","volume":"92","author":"Harder","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.03.018_bib37","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/eye.2014.94","article-title":"Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema","volume":"28","author":"Hanhart","year":"2014","journal-title":"Eye"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016316979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016316979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T14:58:35Z","timestamp":1535900315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642016316979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0161642016316979"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.03.018","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}